Outset Medical, Inc. is a rapidly growing medical technology company that aims to redefine the paradigm of dialysis treatment, transforming the lives of patients with kidney disease and their healthcare providers. Being a visionary company, OM aims to address a dire medical situation affecting millions of people over the world. Their groundbreaking solution is a system known as Tablo, a transformative care system that drastically simplifies kidney dialysis, bringing it within reach of more patients and physicians than ever.
Established in 2003 and headquartered in San Jose, California, OM has dedicated itself to improving the quality and accessibility of care for patients that require dialysis, which is a time-consuming, complicated, and expensive process. It is a public company, listed on NASDAQ with the ticker symbol 'OM.'
Their flagship product, the Tablo Dialysis System, incorporates user-friendly technology that mimics the workings of a traditional, large dialysis machine, all packaged into an easily transportable case about the size of a carry-on bag. This unique system allows patients to receive dialysis treatment either at home or in a clinic, effectively removing the restrictions on a patient's mobility and consequently improving their quality of life. Additionally, the Tablo machine includes a unique feature of being able to produce its dialysis fluid, reducing a significant logistical and storage hurdle.
Beyond the clear benefits to patients, healthcare providers also stand to gain substantially from Outset Medical's technology. This is largely due to the cost efficiencies achieved through Tablo's full-functioning system with its capability to purify water and produce dialysis fluid. Additionally, it reduces the physical footprint and the reliance on specialized, single-purpose rooms for dialysis, increasing operational effectiveness.
Outset Medical is a pioneer, driving innovation in an industry that ripe for change. The company's forward-thinking approach has the potential to disrupt the norm and herald a new era of portable, user-friendly, and cost-effective treatments for kidney disease. As it continues to innovate and push boundaries, Outset Medical is truly a trailblazer in the healthcare industry, setting new precedents with their pioneering technology, their commitment to patients, and their uncompromising dedication to transforming kidney care globally.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Outset Medical reported Q2 2026 revenue of $31.6 million, a 1% year-over-year increase, driven by strong console sales and significant gross margin improvement to 42%. The company reiterated its full-year revenue guidance of $125 million to $130 million, supported by a new $40 million refresh agreement with HCA Healthcare and the upcoming launch of next-gen Tablo. Leadership emphasized enhanced commercial execution and customer success programs as key drivers for future growth and market penetration.
Outset Medical CEO Leslie Trigg sold 3,437 shares of company stock for $15,088.43 to cover tax obligations, reducing her direct holdings by 1.74%. The company's shares fell 7.3% to $4.18, and it reported a quarterly loss of $0.80 per share, though revenue exceeded estimates. Analysts currently have a "Hold" rating on OM with a consensus price target of $10.00, expecting a full-year loss of $3.80 per share.
Outset Medical's General Counsel, John Brottem, sold 2,632 shares of OM stock for $11,554.48 to cover tax obligations from vested equity awards, reducing his direct ownership by 2.92%. This sale occurred as OM shares dropped 7.3% to $4.18, and the company reported a quarterly EPS loss that missed estimates despite revenue exceeding expectations. Analyst sentiment remains mixed with a consensus "Hold" rating and a $10.00 target price, while institutional holdings have generally increased.